Tandem

Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM

Retrieved on: 
星期三, 五月 29, 2024
Diabetes, Health, Medical Devices, Partnership, Tandem, G6, CGM, AID, Insulin, DXCM, Software, Tandem Diabetes Care, G7, Multimedia, Medical device

Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems.

Key Points: 
  • Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems.
  • View the full release here: https://www.businesswire.com/news/home/20240529812588/en/
    Tandem Mobi insulin pump from Tandem Diabetes Care is now compatible with Dexcom G7 Continuous Glucose Monitoring (CGM) System.
  • Tandem’s #1-rated2 t:slim X2™ insulin pump was the first AID system to feature Dexcom G7 integration, as announced in late 2023.
  • With the integration of Dexcom G7, Tandem Mobi users can also experience:
    Additional discretion with Dexcom G7’s low-profile, all-in-one wearable.

AHP Backed Prolerity Clinical Research Appoints Drew Domescik as CFO

Retrieved on: 
星期二, 四月 16, 2024
CFO, Gastroenterology, DSM-IV codes, Investment, PPD, Cardiology, AHP, Tandem, CNS, Patient

NEW YORK, April 16, 2024 /PRNewswire/ -- Prolerity Clinical Research ("Prolerity), a clinical research site network and an AHP portfolio company, announced today that it has appointed Drew Domescik as Chief Financial Officer.

Key Points: 
  • NEW YORK, April 16, 2024 /PRNewswire/ -- Prolerity Clinical Research ("Prolerity), a clinical research site network and an AHP portfolio company, announced today that it has appointed Drew Domescik as Chief Financial Officer.
  • Prolerity currently owns and operates 11 research sites across Louisiana, Florida, New Jersey, and New York.
  • Prolerity is a research site network with therapeutic coverage across complex and challenging phase I-III trials, including gastroenterology, cardiology, CNS and metabolic disease.
  • Prolerity owns New Orleans based Tandem Clinical Research ("Tandem") which has become known for operating best-in-class research sites for NASH/NAFLD and neurodegenerative studies by demonstrating excellence in study feasibility, contracting, patient recruitment, patient retention, and quality.

Burkland Launches Dedicated Services for Clean Energy Startups

Retrieved on: 
星期三, 三月 13, 2024
CHIPS, Consumer, HR, Software as a service, CFO, National Science Foundation, Name, SAN, Accounting, Blog, Perovskite, Aviation, Science, Food, Carbon, PBC, Tandem, Primary energy, Soil, Inflation, Government

SAN FRANCISCO, March 13, 2024 /PRNewswire-PRWeb/ -- Burkland, a full-service fractional CFO, HR, accounting, and tax provider, today announces a new dedicated specialty practice team designed to meet the needs of startups in clean energy. Accounting and financial experts are helping these newly founded companies grow, with strategies tailored to their unique needs and requirements, such as guidance on how to navigate fundraising complexities and manage government grants.

Key Points: 
  • SAN FRANCISCO, March 13, 2024 /PRNewswire-PRWeb/ -- Burkland , a full-service fractional CFO, HR, accounting, and tax provider, today announces a new dedicated specialty practice team designed to meet the needs of startups in clean energy.
  • "Many Burkland clients are hard at work innovating in clean energy, and several have already been recipients of government funds," said Emily Felicelli, Burkland Clean Energy/Grant Accounting Division Lead.
  • "Many Burkland clients are hard at work innovating in clean energy, and several have already been recipients of government funds," said Emily Felicelli , Burkland Clean Energy/Grant Accounting Division Lead.
  • Additional clean energy focus areas for Burkland clients include:
    Burkland experts work with startups across a spectrum of industries, including SaaS, Healthcare, Consumer, Clean Energy, and Fintech, focusing on helping founders succeed.

AHP Backed Prolerity Clinical Research Appoints Jeff Williams as CEO

Retrieved on: 
星期二, 三月 12, 2024
Growth, Practice management, AHP, Cardiology, Patient, CNS, Tandem, Gastroenterology, DSM-IV codes

NEW YORK, March 12, 2024 /PRNewswire/ -- AHP announced today that it has appointed Jeff Williams as Chief Executive Officer for Prolerity Clinical Research ("Prolerity"), a clinical research site management network.

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- AHP announced today that it has appointed Jeff Williams as Chief Executive Officer for Prolerity Clinical Research ("Prolerity"), a clinical research site management network.
  • Prolerity currently owns and operates 11 research sites across Louisiana, Florida, New Jersey, and New York.
  • Previously, Jeff co-founded Clinipace Worldwide, a contract research organization where he served as CEO for 14 years.
  • Most recently he was CEO of MindPath Care Centers, a PE backed outpatient behavioral health platform serving the southeast United States.

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期三, 三月 6, 2024
Tandem, AML, Neoplasm, FDA, Quality of life, Food, Data, AACR, Histocompatibility, Society, MDS, Transplant, Therapy, Food and Drug Administration, Patient, Clinical trial, TCR, IND, KOL, MAGE-A1, Cancer, Pharmaceutical industry

The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.

Key Points: 
  • The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
  • With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development.
  • Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months.
  • The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
星期五, 二月 23, 2024
Tandem, Therapy, Infection, MD, TCT, FDA, Bone marrow, Cell, Health, Hematology, Society, Duke Cancer Institute, Science, White, Non-Hodgkin lymphoma, Patient, Fungal infection, NK, NAM, Rated R, Transplant, Rituximab, Cytokine release syndrome, EAP, Lymphoma, Pharmaceutical industry

BOSTON, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today presented data highlighting its expanded access program (EAP) for FDA-approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and Phase 1 data for its allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.

Key Points: 
  • The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.
  • “The data presented at Tandem provide further evidence of the potential of Gamida Cell’s nicotinamide (NAM) technology to develop potentially curative therapies by expanding and enhancing cells,” said Ronit Simantov, MD, Chief Medical and Scientific Officer of Gamida Cell.
  • It allowed for institutional variability in conditioning regimens and supportive care, more closely reflecting the real-world environment.
  • Patients were heavily pretreated with a median of six prior lines of therapy including CAR-T cell therapy and hematopoietic stem cell transplant.

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Retrieved on: 
星期二, 三月 5, 2024
Software, Health, Diabetes, Medical Devices, Health Technology, Wearables, Mobile Technology, Technology, Clinical Trials, Tandem, HCP, CGM, Apple Watch, G6, Diabetic ketoacidosis, AID, DXCM, G7, Hypoglycemia, GLP1, Conference, Type 2 diabetes, ATTD, Type 2, Patient, Insulin, Apple, Mortality, Pharmaceutical industry

Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.

Key Points: 
  • Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes.
  • Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.
  • Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023.
  • Further demonstrating the value of AID systems powered by Dexcom CGM, Dexcom will showcase recently published evidence at ATTD 2024.

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Retrieved on: 
星期二, 二月 13, 2024
Wearables, Mobile Technology, Apps, Applications, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Health, Tandem, Convatec, Dexcom, CGM, IPhone, Multimedia, G6, Compatibility, Control, Insulin, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.
  • View the full release here: https://www.businesswire.com/news/home/20240213214991/en/
    Tandem Mobi, the world’s smallest, durable insulin delivery system, now shipping in the United States.
  • The Tandem Customer Care team is available now to help determine eligibility and potential timing of pump shipments for customers.
  • People living with diabetes interested in the Tandem Mobi system can start the order process at: www.tandemdiabetes.com/mobi .

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
星期四, 一月 18, 2024
Syndrome, Patient, Therapy, Transplant, MDS, TCR, Acute myeloid leukemia, ALL, Society, Cancer, Acute leukemia, Tandem, HCT, AML, Abstract (summary)

WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online. The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) (NCT05473910). The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.

Key Points: 
  • WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online.
  • The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
  • The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.
  • Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center)
    A copy of the presentation materials will be added to the “ Events and Presentations ” section of the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.

A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2

Retrieved on: 
星期一, 一月 15, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Diabetes, Clinical Trials, Health Technology, Software, Biotechnology, Health, Data Management, CGM, FIN Atlantic Film Festival, Dexcom, EASD, Associate professor, Partnership, Hypoglycemia, University, Risk, DXCM, Diabetic retinopathy, Insulin, G7, Tandem Diabetes Care, AID, Tandem, University of Nottingham, Medical device

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa.
  • The announcement comes just a month after the system launched in the United States and combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2.
  • Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the t:slim X2 insulin pump with Control-IQ technology5.
  • To learn more and to get started with Dexcom G7 and the Tandem t:slim X2 insulin pump, visit Dexcom.co.uk/tandem.